Overview
Met-Enkephalin (ME), also known as the Opioid Growth Factor (OGF), is an endogenous pentapeptide that functions as a neurotransmitter and neuromodulator within the central nervous system (CNS). Discovered in 1975, ME activates the μ and δ opioid receptors, contributing to pain modulation, immune regulation, and euphoria. Unlike traditional opioids, ME uniquely operates through the OGF-OGFr axis to regulate cellular growth, showing promise as both an anti-cancer agent and immune modulator.
Met-Enkephalin (ME), also known as the Opioid Growth Factor (OGF), is an endogenous pentapeptide that functions as a neurotransmitter and neuromodulator within the central nervous system (CNS). Discovered in 1975, ME activates the μ and δ opioid receptors, contributing to pain modulation, immune regulation, and euphoria. Unlike traditional opioids, ME uniquely operates through the OGF-OGFr axis to regulate cellular growth, showing promise as both an anti-cancer agent and immune modulator.
Key Benefits
- Cancer Therapy: Regulates cell growth via the OGF-OGFr axis, showing potential in breast, colon, renal, pancreatic, ovarian, and melanoma cancers.
- Immune Modulation: Acts as a cytokine, enhancing immune function at low concentrations and modulating inflammation for autoimmune support.
- LDN Alternative: May serve as a natural substitute for low-dose naltrexone (LDN), supporting immune balance and pain relief by boosting enkephalin activity.
Mechanism of Action
- Receptor Binding: Binds to μ and δ opioid receptors in the CNS, modulating neurotransmitter release and cellular interactions.
- OGF-OGFr Axis: Regulates cellular growth in both normal and cancerous cells, producing anti-proliferative effects and offering a targeted approach in oncology.
Research and Applications
- Anti-Cancer Properties: Clinical studies show ME inhibits tumor growth across multiple cancer types (breast, colon, renal, pancreatic, ovarian, melanoma) without negatively affecting hematologic or biochemical parameters.
- Immune System Support: Enhances immune function by modulating cytokines and cellular communication, with potential for autoimmune conditions such as multiple sclerosis.
- LDN Substitute Potential: Mimics some of the benefits of low-dose naltrexone by naturally boosting enkephalins, making it a candidate for immune support and pain regulation therapies.
Product Information
- Peptide Type: Pentapeptide
- Primary Actions: Cancer therapy, immune modulation, neurotransmitter regulation
- Structure: Methionine-Enkephalin (Tyr-Gly-Gly-Phe-Met)
- Storage: Store frozen until first use; refrigerate at 2°C – 8°C for up to 56 days
